Business Overview

Echo Therapeutics (OTCBB: ECTE) is developing its Symphony™ tCGM System, a novel, non-invasive (needle-free), wireless, transdermal continuous transdermal glucose monitoring (tCGM) system for diabetes home use and hospital critical care markets, and a pipeline of specialty pharmaceutical products incorporating its proprietary AzoneTS™ transdermal drug reformulation technology.

Echo is leveraging its unique, long-term strategic development relationship with Cato Research, a global contract research and development organization (CRO) and an affiliate of Echo's largest institutional investor, Cato BioVentures, to develop its pipleine efficiently and cost-effectively.

Edit Page Add Page